
Acutaas Chemical Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- FY24 revenue growth target revised downward to 18%-22% from earlier 22%-25%, mainly due to pricing erosion despite volume growth of 20%-25%.
- Volume growth expected to remain strong; value/realization affected by pricing pressures.
- Muted performance expected in FY24 due to delayed product launches and acquisition/integration of Baba Fine Chemicals; FY25 anticipated to be better than both FY23 and FY24.
- Baba Fine Chemicals integration year in FY24; exponential growth targeted in coming years with aim for Rs. 200-250 crore topline in 4-5 years.
- Full utilization of Ankleshwar facility capacity targeted by FY27 with ongoing pipeline discussions.
- Specialty chemicals segment targeting to achieve 2.5x growth over next couple of years.
- New product launches (e.g., UV absorber, electrolyte additives) expected to contribute revenue from Q3 FY24 onwards.
- Fermion contract revenues expected to ramp up fully by H2 FY25.
See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Acutaas Chemical management said on order book — free account, 30 seconds.
Capex plans
Yes- Ami Organics has approved a 16-megawatt captive solar power plant project with a CAPEX of approximately Rs. 65-70 crores; installation is expected to complete by the end of the financial year.
- Additionally, a 5-megawatt solar power plant is already in progress, which will help offset electricity expenses once operational.
- CAPEX for H1 FY24 was Rs. 105 crores, with another Rs. 100-110 crores expected by year-end.
- The Ankleshwar facility, acquired from Gujarat Organics with an investment of around Rs. 190 crores, will be operational by mid-December 2023, ramping up in Q4 FY24 to contribute to revenues.
- The Ankleshwar site's capacity includes 33% allocated to the Fermion contract (fully booked) with 66% capacity free for future demand till FY27.
- Ongoing focus on expanding strategic partnerships and commercial supplies—e.g., the Fermion contract with plans to start supplying two more intermediates commercially in H2 FY25.
Track Acutaas Chemical — get its next earnings analysis in your feed
How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?
Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem